SCHEMBL3605304

SCHEMBL3605304

Cc1ccc(-c2ccc3c(-c4ccccc4)nn(CC(=O)NCCN(C)C4CCCCC4)c3c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.47
POLB P06746 3/20 0.45
TSHR P16473 3/20 0.43
HTT P42858 2/20 0.43
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
KDM4E B2RXH2 3/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 2/20 0.41
TP53 P04637 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 1/20 0.40
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604327 0.93 KDM4E (0.41) THRBPOLBTSHRHTTKMT2A
SCHEMBL3596903 0.90 KDM4E (0.40) THRBPOLBTSHRHTTKMT2A
SCHEMBL13115657 0.87 KDM4E (0.45) POLBTSHRKMT2AMEN1KDM4E
SCHEMBL14396904 0.86 KDM4E (0.42) POLBTSHRHTTKMT2AMEN1
SCHEMBL13115712 0.86 KDM4E (0.38) THRBPOLBTSHRHTTKMT2A
SCHEMBL3605305 0.85 THRB (0.48) THRBPOLBTSHRHTTKMT2A
SCHEMBL3586854 0.80 KDM4E (0.42) POLBTSHRKMT2AKDM4EUSP2
SCHEMBL3591258 0.78 MAPK1 (0.45) POLBTSHRKMT2AMEN1MAPK1
SCHEMBL3604329 0.77 POLB (0.41) THRBPOLBTSHRHTTKDM4E
SCHEMBL13115590 0.77 ATM (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 THRB 1690/4885POLB 4479/4885TSHR 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.